Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Earlier this month, Pfizer filed a lawsuit (HP-2022-000016) in the Royal Courts of Justice in London, seeking to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

The shots are important for both Pfizer and GSK as they look to build new franchises before top-selling drugs face generic competition later this decade. Pfizer is also contending with activist ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding ...